Add to ORKGA critical appraisal and clinical application of Hiatt H, Fowkes G, Heizer G, et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med. 2017;376:32-40. doi: 10.1056/NEJMoa1611688
Background: High-quality evidence from trials directly comparing single antiplatelet therapies in sy...
Background The literature on antiplatelet therapy for peripheral artery disease has historically be...
AbstractObjectives: Antiplatelet agents are commonly prescribed to reduce the risk of myocardial inf...
Background Peripheral artery disease is considered to be a manifestation of systemic atherosclerosis...
Background: Peripheral artery disease is considered to be a manifestation of systemic atherosclerosi...
Background: In patients with symptomatic peripheral artery disease with a history of limb revascular...
BACKGROUND -In patients with symptomatic peripheral artery disease (PAD) with a history of limb r...
There is a lack of consensus regarding which type of antiplatelet agent should be used in patients w...
<div><p>There is a lack of consensus regarding which type of antiplatelet agent should be used in pa...
BACKGROUND Despite overwhelming data demonstrating the efficacy of antiplatelet therapy in heart ...
There is a lack of consensus regarding which type of antiplatelet agent should be used in patients w...
Patients with peripheral artery disease (PAD) are at heightened risk of cardiovascular morbidity and...
-In patients with symptomatic peripheral artery disease (PAD) with a history of limb revascularizati...
P eripheral artery disease (PAD) was identified by theInstitute of Medicine as one of the top 100 pr...
BACKGROUND: High-quality evidence from trials directly comparing single antiplatelet therapies in sy...
Background: High-quality evidence from trials directly comparing single antiplatelet therapies in sy...
Background The literature on antiplatelet therapy for peripheral artery disease has historically be...
AbstractObjectives: Antiplatelet agents are commonly prescribed to reduce the risk of myocardial inf...
Background Peripheral artery disease is considered to be a manifestation of systemic atherosclerosis...
Background: Peripheral artery disease is considered to be a manifestation of systemic atherosclerosi...
Background: In patients with symptomatic peripheral artery disease with a history of limb revascular...
BACKGROUND -In patients with symptomatic peripheral artery disease (PAD) with a history of limb r...
There is a lack of consensus regarding which type of antiplatelet agent should be used in patients w...
<div><p>There is a lack of consensus regarding which type of antiplatelet agent should be used in pa...
BACKGROUND Despite overwhelming data demonstrating the efficacy of antiplatelet therapy in heart ...
There is a lack of consensus regarding which type of antiplatelet agent should be used in patients w...
Patients with peripheral artery disease (PAD) are at heightened risk of cardiovascular morbidity and...
-In patients with symptomatic peripheral artery disease (PAD) with a history of limb revascularizati...
P eripheral artery disease (PAD) was identified by theInstitute of Medicine as one of the top 100 pr...
BACKGROUND: High-quality evidence from trials directly comparing single antiplatelet therapies in sy...
Background: High-quality evidence from trials directly comparing single antiplatelet therapies in sy...
Background The literature on antiplatelet therapy for peripheral artery disease has historically be...
AbstractObjectives: Antiplatelet agents are commonly prescribed to reduce the risk of myocardial inf...